Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORTAD quality-of-life study of Plenadren versus Cortison in newly diagnosed primary adrenal insufficiency
2024-512888-31-00Phase 4Authorised
- Sponsor
- Helse Bergen
- Start
- Aug 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hydrocortisone and cortisone in Addison's disease (2 arms), sponsored by Helse Bergen. Primary endpoint: Health-related quality of life score. Planned start Aug 2023; status: authorised.
02
Drugs
hydrocortisonecortisone
03
Conditions
Addison's disease
Beyond the preview
Go deeper on 2024-512888-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512888-31-00.